A phase 1b dose-escalation study of carfilzomib in combination with thalidomide and dexamethasone in patients with relapsed/refractory systemic immunoglobulin light chain amyloidosis
Sriram Ravichandran(The Royal Free Hospital), Ashutosh Wechalekar(University College Hospital), Philip N. Hawkins(The Royal Free Hospital), Jamie B. Oughton, Julian D. Gillmore(Alnylam Pharmaceuticals (United States)), Bhuvan Kishore(National Health Service), Sarah Brown(University of Leeds), Andrew Hall(University of Leeds), Matthew Jenner(University Hospital Southampton NHS Foundation Trust), Alexandra Pitchford(University of Leeds), Sajitha Sachchithantham(The Royal Free Hospital), Helen J. Lachmann(Royal Free London NHS Foundation Trust), Shameem Mahmood(The Royal Free Hospital), Mamta Garg(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo)
Cited by 9
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
NALP3 Forms an IL-1β-Processing Inflammasome with Increased Activity in Muckle-Wells Autoinflammatory Disorder
|Immunity|2004|1.7k
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
|New England Journal of Medicine|2021|1.7k